Natera, Inc. $NTRA Shares Purchased by Summit Partners Public Asset Management LLC

Summit Partners Public Asset Management LLC increased its stake in shares of Natera, Inc. (NASDAQ:NTRA) by 229.9% in the 4th quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 407,653 shares of the medical research company’s stock after purchasing an additional 284,066 shares during the period. Natera accounts for approximately 1.9% of Summit Partners Public Asset Management LLC’s investment portfolio, making the stock its 7th biggest position. Summit Partners Public Asset Management LLC owned approximately 0.29% of Natera worth $93,389,000 at the end of the most recent reporting period.

Other hedge funds have also recently modified their holdings of the company. Palladiem LLC acquired a new position in shares of Natera during the 4th quarter worth about $31,000. Bank of Jackson Hole Trust raised its holdings in Natera by 103.8% in the 4th quarter. Bank of Jackson Hole Trust now owns 163 shares of the medical research company’s stock valued at $37,000 after acquiring an additional 83 shares during the last quarter. Flagship Harbor Advisors LLC acquired a new stake in Natera in the 4th quarter valued at about $41,000. Greenline Wealth Management LLC acquired a new stake in Natera in the 4th quarter valued at about $41,000. Finally, Horizon Investments LLC acquired a new stake in Natera in the 3rd quarter valued at about $32,000. Institutional investors and hedge funds own 99.90% of the company’s stock.

Insider Activity

In related news, CEO Steven Leonard Chapman sold 41,124 shares of the stock in a transaction that occurred on Thursday, June 4th. The shares were sold at an average price of $221.03, for a total transaction of $9,089,637.72. Following the completion of the transaction, the chief executive officer owned 108,743 shares of the company’s stock, valued at approximately $24,035,465.29. This trade represents a 27.44% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CFO Michael Burkes Brophy sold 3,070 shares of the stock in a transaction that occurred on Wednesday, April 29th. The stock was sold at an average price of $193.74, for a total transaction of $594,781.80. Following the sale, the chief financial officer owned 58,291 shares in the company, valued at approximately $11,293,298.34. This trade represents a 5.00% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders have sold a total of 159,378 shares of company stock worth $34,640,860 in the last three months. 5.05% of the stock is currently owned by corporate insiders.

Natera Stock Performance

NASDAQ:NTRA opened at $220.11 on Wednesday. The stock has a market capitalization of $31.52 billion, a P/E ratio of -135.04 and a beta of 1.56. The company has a 50 day moving average price of $206.92 and a 200 day moving average price of $215.57. Natera, Inc. has a fifty-two week low of $131.81 and a fifty-two week high of $256.36.

Wall Street Analysts Forecast Growth

NTRA has been the subject of a number of recent research reports. Wells Fargo & Company increased their price objective on shares of Natera from $215.00 to $220.00 and gave the company an “equal weight” rating in a report on Friday, May 8th. William Blair initiated coverage on shares of Natera in a report on Tuesday, April 14th. They issued an “outperform” rating for the company. Morgan Stanley cut their price objective on shares of Natera from $265.00 to $250.00 and set an “overweight” rating for the company in a report on Tuesday, March 3rd. The Goldman Sachs Group initiated coverage on shares of Natera in a report on Friday, June 5th. They issued a “neutral” rating and a $245.00 price objective for the company. Finally, Wall Street Zen downgraded shares of Natera from a “buy” rating to a “hold” rating in a report on Saturday, May 9th. Two equities research analysts have rated the stock with a Strong Buy rating, fourteen have assigned a Buy rating, four have issued a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average target price of $256.53.

Natera Company Profile

Natera is a global diagnostics company that develops and commercializes cell-free DNA and other genetic testing technologies for clinical applications. The company focuses on three principal areas: reproductive health (including non-invasive prenatal testing and carrier screening), oncology (tumor-informed assays for minimal residual disease and recurrence monitoring), and organ transplantation (cell-free DNA tests to detect allograft injury). Natera combines laboratory testing, proprietary bioinformatics, and clinical reporting to deliver personalized genetic information to clinicians and patients.

Key product offerings include Panorama, a non-invasive prenatal test that screens for fetal chromosomal abnormalities and select single-gene conditions; Horizon carrier screening for inherited conditions; Signatera, a personalized, tumor-informed assay used for detecting minimal residual disease and monitoring treatment response in cancer patients; and Prospera, a donor-derived cell-free DNA test used to assess the risk of organ rejection.